Global IVD Market - Description In vitro diagnostics (IVD) tests are medical devices (instruments, reagents, and systems) intended to determine medical information for the diagnosis of a disease or condition. IVD tests are performed outside living or ....see more
The global cancer biomarkers market is expected to grow from USD 179 million in 2021 to USD 299 million by 2026, at a compound annual growth rate (CAGR) of 10.7% during the forecast period.The major players F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).
The in-vitro diagnostics market is expected to grow from USD 98.2 billion in 2021 to USD 113.1 billion by 2026, at a CAGR of 2.9% during the forecast period. Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).
The sepsis diagnostics market is expected to grow from USD 503 million in 2021 to USD 771 million by 2026, at a CAGR of 8.9% during the forecast period. Some of the prominent players in the sepsis diagnostics markets market are bioMérieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), among others.
The lateral flow assays market is expected to grow USD 12.6 billion by 2026, at a CAGR of 2.0% during the forecast period. The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Bio-Rad Laboratories (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).
The global blood screening market is expected to grow from USD 2.5 billion in 2021 to USD 3.8 billion by 2026, at a compound annual growth rate (CAGR) of 8.4% during the forecast period.The major players Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).
The anatomic pathology market is expected to grow from USD 35.1 billion in 2021 to USD 49.1 billion by 2026, at a CAGR of 7.0% during the forecast period. The major players in the anatomic pathology market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), and PHC Holdings Corporation (Japan).
The allergy diagnostics market is projected to reach USD 8.2 billion by 2026, at a CAGR of 11.1% during the forecasting period. The major players operating in this market are Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).
The global urinalysis market size is projected to reach USD 4.9 billion by 2026, at a CAGR of 7.2% during the forecasting period. The major players operating in this market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), Abbott Laboratories (US), Danaher Corporation (US), Sysmex Corporation (Japan), Quidel Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), EKF Diagnostics (UK), Thermo Fisher Scientific Inc. (US), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (US), 77 Elektronika Kft. (Hungary), URIT Medical Electronic Group Co., Ltd. (China), Dirui Industrial Co., Ltd. (China), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BIOBASE Group (China), ERBA Mannheim (UK), Alphatech Scientitfic (Peru), Teco Diagnostics (US), Analyticon Technologies AG (Germany), Bioway Biological Technology Co. Ltd. (China), High Technology Inc. (US) and Agappe Diagnostics Ltd. (India).
The global immunoassay market is expected to grow from USD 28.4 billion in 2021 to USD 39.0 billion by 2026, at a compound annual growth rate (CAGR) of 6.6% during the forecast period.Danaher (US), Thermo Fisher Scientific (US), Abbott Laboratories (US) and Roche (Switzerland).
The global clinical chemistry analyzers market is expected to grow from 12.3 billion in 2021 to USD 15.2 billion by 2026, at a compound annual growth rate (CAGR) of 4.3% during the forecast period.are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).
The Blood Culture Tests Market is expected to grow from USD 4.0 billion in 2020 to USD 6.1 billion by 2025, at a CAGR of 8.9% during the forecast period. Major players operating in the blood culture tests market include Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), bioMérieux SA (France), Luminex Corporation (US), Danaher Corporation (US), Bruker Corporation (US), IRIDICA (US), Roche Diagnostics (Switzerland), T2 Biosystems, Inc. (US), Anaerobe Systems, Inc. (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan), BINDER GmbH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio, Inc. (US), Axiom Laboratories (India), and HiMedia Laboratories Pvt. Ltd. (India).
The cardiac marker testing market is expected to grow from USD 3.6 billion in 2020 to USD 5.5 billion by 2025, at a compound annual growth rate (CAGR) of 8.9 % during the forecast period.The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well.
The HLA Typing for Transplant Market is expected to grow from USD 656 million in 2019 to USD 968 million by 2025, at a CAGR of 6.7% during the forecast period. Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), and Immucor, Inc. (US). Others are Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), Omixon (Hungary), Becton, Dickinson and Company (US), Fujirebio, Inc. (Japan), and TBG Diagnostics Ltd. (Australia)
The blood group typing market is projected to reach USD 3.12 Billion by 2021 from USD 1.95 Billion in 2016, at a CAGR of 9.8%. The increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences are the major factors fueling the growth of this market.
The HIV diagnosis market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021. Factors such as the growing worldwide prevalence of HIV/AIDS, increasing number of blood transfusions and blood donations, benefits offered by point-of-care instruments and kits, and increasing government initiatives are expected to drive the growth of the HIV diagnosis market worldwide.
The global respiratory diagnostics market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021. In this report, the global respiratory diagnostics market is broadly segmented by product and service, test type, disease, end user, and region.
is 2015 and the forecast for the market size is provided for the period between 2015 and 2020. In the current market scenario, biochips are increasingly adopted in various applications in the field of genomics, drug discovery, and proteomics. In addition, the development of targeted and personalized medicines for the treatment of cancer and technological advancements in biochips are also supporting the growth of biochip products.
Radioimmunoassay (RIA) is an in-vitro assay technique that is used to measure the concentration of antigens in blood. RIA encompasses the separation of protein from a mixture by using the specificity of antibody- antigen binding and their quantitation by using radioactivity. The global radioimmunoassay (RIA) market was valued at $345.2 Million in 2014 and is expected to reach $428.4 Million in 2020 at a CAGR of 3.5% from 2015-2020.